Evidence map›Paper›PMID 22973447›Full record

ArticlePloS one2012

Differential activities of the two closely related withanolides, Withaferin A and Withanone: bioinformatics and experimental evidences.

Kirti Vaishnavi, Nishant Saxena, Navjot Shah, Rumani Singh, Kavyashree Manjunath, M Uthayakumar, Shankar P Kanaujia, Sunil C Kaul, Kanagaraj Sekar, Renu Wadhwa

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
17.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 127 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Liver Dangers of Herbal Products: A Case Report of Ashwagandha-Induced Liver Injury.International journal of environmental research and public health · 2023
    Article
  10. Review
  11. Pharmaceutics · 2022
    Review
  12. Article
  13. Why is Mortalin a Potential Therapeutic Target for Cancer?Frontiers in cell and developmental biology · 2022
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Kirti VaishnaviSupercomputer Education and Research Centre, Indian Institute of Science, Bangalore, India.
Nishant Saxena
Navjot Shah
Rumani Singh
Kavyashree Manjunath
M Uthayakumar
Shankar P Kanaujia
Sunil C Kaul
Kanagaraj Sekar
Renu Wadhwa
Indian Institute of Science Bangalore · INNational Institute of Advanced Industrial Science and Technology · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeWithanolides are naturally occurring chemical compounds. They are secondary metabolites produced via oxidation of steroids and structurally consist of a steroid-backbone bound to a lactone or its derivatives. They are known to protect plants against herbivores and have medicinal value including anti-inflammation, anti-cancer, adaptogenic and anti-oxidant effects. Withaferin A (Wi-A) and Withanone (Wi-N) are two structurally similar withanolides isolated from Withania somnifera, also known as Ashwagandha in Indian Ayurvedic medicine. Ashwagandha alcoholic leaf extract (i-Extract), rich in Wi-N, was shown to kill cancer cells selectively. Furthermore, the two closely related purified phytochemicals, Wi-A and Wi-N, showed differential activity in normal and cancer human cells in vitro and in vivo. We had earlier identified several genes involved in cytotoxicity of i-Extract in human cancer cells by loss-of-function assays using either siRNA or randomized ribozyme library. METHODOLOGY/PRINCIPAL

findingsIn the present study, we have employed bioinformatics tools on four genes, i.e., mortalin, p53, p21 and Nrf2, identified by loss-of-function screenings. We examined the docking efficacy of Wi-N and Wi-A to each of the four targets and found that the two closely related phytochemicals have differential binding properties to the selected cellular targets that can potentially instigate differential molecular effects. We validated these findings by undertaking parallel experiments on specific gene responses to either Wi-N or Wi-A in human normal and cancer cells. We demonstrate that Wi-A that binds strongly to the selected targets acts as a strong cytotoxic agent both for normal and cancer cells. Wi-N, on the other hand, has a weak binding to the targets; it showed milder cytotoxicity towards cancer cells and was safe for normal cells. The present molecular docking analyses and experimental evidence revealed important insights to the use of Wi-A and Wi-N for cancer treatment and development of new anti-cancer phytochemical cocktails.

Indexed as

Models, Molecularbeta-GalactosidaseBlotting, WesternCell DeathCell LineCell Line, TumorCell ProliferationCell SurvivalComputational BiologyCyclin-Dependent Kinase Inhibitor p21HSP70 Heat-Shock ProteinsHumansImmunoprecipitationMedicine, AyurvedicMolecular StructureNF-E2-Related Factor 2Ashwagandhabeta-GalactosidaseCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21HSP70 Heat-Shock ProteinsmortalinNFE2L2 protein, humanNF-E2-Related Factor 2Plant ExtractsTetrazolium SaltsThiazolesthiazolyl blueTriterpenesTumor Suppressor Protein p53withaferin AWithanolideswithanone

Identifiers

PMID22973447
PMCPMC3433425
OpenAlexW2115016535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.